San Francisco, Jul. 25, 2017 – Recardio is participating in the European Society of Cardiology Congress in Barcelona.
The Conference is the biggest cardiology event in the world hosting almost 30.000 cardiovascular medical professionals during a 5-day event. The meeting is focusing on the proper way to present, share, debate the latest research in cardiology and how this can improve prevention, diagnosis, treatment and most important the lives of patients.
The European Society of Cardiology Congress is held on August 26-30, 2017 at the Fira Gran Via in Barcelona, Spain.
The company will present and discuss its last update from the phase 1 study and its phase 2 clinical development program starting enrollment in the fourth quarter of 2017.
More information about the clinical development program is available by visiting the following link.
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, Dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is initiating a Phase 1/2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/